Patents Assigned to Inserm
  • Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8
    Patent number: 8772243
    Abstract: The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: July 8, 2014
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Julien Cherfils, Herve Fridman, Isabelle Cremer
  • Methods for diagnosing and treating a pathology associated with a synonymous mutation occuring within a gene of interest
    Patent number: 8771937
    Abstract: The present invention relates to a method for diagnosing and/or prognosing a pathology (such as inflammatory disease, especially Crohn disease) associated with a synonymous mutation occurring within a gene of interest (such as IRGM, NOD2 or BSN) in a subject and to a method for treating such pathology in a subject.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: July 8, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), The Nice Sophia Antipolis University
    Inventors: Patrick Brest, Paul Hofman, Baharia Mograbi
  • Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma
    Patent number: 8771691
    Abstract: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: July 8, 2014
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Patricia Forgez, Marco Alifano
  • METHOD FOR PREDICTING THE RISK OF DEVELOPING A COLONIC NEOPLASIA
    Publication number: 20140186366
    Abstract: The present invention relates to an in vitro method for determining whether a patient having hyperplastic polyps is at risk of developing a colonic neoplasia after resection of said hyperplastic polyps, said method comprising the step of determining the level of progastrin expression in a tissue sample of a hyperplastic polyp obtained from said patient.
    Type: Application
    Filed: May 31, 2012
    Publication date: July 3, 2014
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER - TOULOUSE III
    Inventors: Catherine Seva, Catherine Do, Audrey Ferrand, Julien Palasse, Marie-Bernadette Delisle
  • METHOD FOR PREDICTING INSULINOPENIC TYPE 2 DIABETES
    Publication number: 20140186829
    Abstract: The present invention relates to an in vitro method, for predicting a risk of onset of type 2 diabetes in a subject, which method comprises the steps of: a) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) comparing said measured concentration of bacterial 16S rDNA to a threshold level; wherein a measured concentration of bacterial 16S rDNA higher than the threshold level is indicative of an increased risk of onset of type 2 diabetes in the subject, and a measured concentration of bacterial 16S rDNA lower than the threshold level is indicative of a decreased risk of onset of type 2 diabetes in the subject.
    Type: Application
    Filed: April 2, 2012
    Publication date: July 3, 2014
    Applicants: CHU De Toulouse, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Remy Burcelin, Jacques Amar, Beverly Balkau
  • Methods and Compositions Comprising AMPK Activator (Metformin/Troglitazone) for the Treatment of Myotonic Dystrophy Type 1 (DM1)
    Publication number: 20140187595
    Abstract: The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator <eq.metformin or troglizazone>.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 3, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Sandrine Baghdoyan, Marc Peschanski, Delphine Laustriat, Jacqueline Gide
  • Non Human Animal Models for Increased Retinal Vascular Permeability
    Publication number: 20140186960
    Abstract: The present invention relates to a non human animal model for increased retinal vascular permeability wherein said increased retinal vascular permeability is induced by inhibiting in Müller cells of said animal the expression of a gene encoding for Dp71 or a dystrophin associated protein (DAP). Furthermore, the present invention relates to methods and compositions for the treatment of a disease associated with an increased retinal vascular permeability in a subject in need thereof.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicant: Institut National De La Sante et De La Recherche Medicale (INSERM)
    Inventors: Abdoulaye Sene, Ramin Tadayoni, Jose Sahel, Alvaro Rendon
  • METHODS FOR DETERMINING THE EXPRESSION LEVEL OF A GENE OF INTEREST INCLUDING CORRECTION OF RT-QPCR DATA FOR GENOMIC DNA-DERIVED SIGNALS
    Publication number: 20140186845
    Abstract: The present invention relates to methods for determining the expression level of a gene of interest in a nucleic acid sample by RT-qPCR. More specifically, procedures for determining the impact of a gDNA contamination on the measured total signal have been developed allowing the correction of the signal originating from the above said gDNA. A further aspect of the invention refers to a mean by which the sensitivity qPCR primers toward gDNA can be determined.
    Type: Application
    Filed: June 14, 2012
    Publication date: July 3, 2014
    Applicants: UNIVERSITE PAUL SABATIER - TOULOUSE III, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Henrik Laurell, Mikael Kubista, Jason Iacovoni
  • New Inhibitors of Cyclophilins and Uses Thereof
    Publication number: 20140179687
    Abstract: The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particular H, and R5 an alkyl group, R6 is in particular H or an alkyl group, and R7 is in particular an aryl group, for its use in the prevention and/or the treatment of viral pathologies or infections.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 26, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Francois Guichou, Lionel Colliandre, Hakim Ahmed-Belkacem, Jean-Michael Pawlotsky
  • NOVEL ANTIGEN PEPTIDE AND USES THEREOF
    Publication number: 20140178394
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: June 26, 2014
    Applicants: UNIVERSITE D'AIX MARSEILLE, INSERM (Insititut Nationa de la Sante et de la Rec Recherche Medicals), INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc Lopez, Daniel Olive
  • METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL
    Publication number: 20140178308
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: July 27, 2012
    Publication date: June 26, 2014
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: William Rostene, Christophe Baudouin, David Godefroy, Alexandre Denoyer
  • SELECTIVE CULTURE MEDIUM AND METHOD FOR DETECTING CARBAPENEM-RESISTANT BACTERIA IN A TEST SAMPLE
    Publication number: 20140178922
    Abstract: The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium.
    Type: Application
    Filed: July 5, 2012
    Publication date: June 26, 2014
    Applicants: UNIVERSITE PARIS SUD (PARIS 11), Institut National de la Sante et de la Recherche Medicale (INSERM), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Delphine Girlich, Laurent Poirel, Patrice Nordmann
  • METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
    Publication number: 20140179767
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 26, 2014
    Applicants: INSERM (Institut National de la Sante et de la Racherche Medicale), GENETHON, CNRS (Centre National de la Racherche Scientifique
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman
  • Host cell kinases as targets for antiviral therapies against HCV infection
    Patent number: 8759010
    Abstract: The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: June 24, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thomas Baumert, Joachim Lupberger
  • Methods for selecting oocytes and competent embryos with high potential for pregnancy outcome
    Patent number: 8754014
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: June 17, 2014
    Assignee: Institut National de la Sante et de la Recherche Medical (INSERM)
    Inventors: Samir Hamamah, John De Vos, Said Assou
  • SILYLATED BIOMOLECULE-BASED HYDROGEL FOR CULTURING CARDIOMYOCYTES AND STEM CELLS, AND USE OF THE HYDROGEL THEREOF FOR TREATING HEART FAILURE
    Publication number: 20140161775
    Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.
    Type: Application
    Filed: June 4, 2012
    Publication date: June 12, 2014
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CHU NANTES, UNIVERSITE DE NANTES
    Inventors: Pierre Weiss, Eva Mathieu, Jérôme Guicheux, Patricia Lemarchand
  • FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau Dysfunction
    Publication number: 20140163021
    Abstract: Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 12, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Etienne Baulieu, Beatrice Chambraud
  • BOOSTING HUMAN DENDRITIC CELL DEVELOPMENT, HOMEOSTASIS AND FUNCTION IN XENOGRAFTED IMMUNODEFICIENT MICE
    Publication number: 20140165220
    Abstract: The present invention relates to a transgenic animal model system based on the development of transgenic mice bearing components of the human immune system. Specifically, the invention relates to a Flk2 deficient Rag?/??c?/? transgenic mouse and the engraftment of said mouse with human hematopoietic stem cells. The present invention further provides methods for increasing the numbers of functionally competent human dendritic cells and the hematopoietic targets cells that they interact with in said transgenic mouse through the administration of Flk2L. The transgenic animal model system of the invention may be used for testing human vaccine candidates, for screening potential immune adjuvants and for developing novel therapeutics.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Applicants: INSTITUT PASTEUR, INSERM (Institut National de la Santé et de la Recherche)
    Inventors: James Di SANTO, Jean-Jacques MENTION
  • GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI
    Publication number: 20140161793
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 12, 2014
    Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche Scientifique
    Inventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
  • Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
    Patent number: 8748493
    Abstract: The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a biological sample obtained from a subject.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: June 10, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Karine Clement, Michele Guerre Millo, Nadia Naour